Contrasting Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and DexCom (NASDAQ:DXCM)

DexCom (NASDAQ:DXCM) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Profitability

This table compares DexCom and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DexCom	17.22%	31.40%	10.58%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Valuation & Earnings

This table compares DexCom and Health Sciences Acquisitions Co. 2″s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$3.62 billion	9.46	$541.50 million	$1.67	52.52
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A

DexCom has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Institutional & Insider Ownership

97.8% of DexCom shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for DexCom and Health Sciences Acquisitions Co. 2, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0	4	12	2	2.89
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00

DexCom presently has a consensus target price of $99.29, suggesting a potential upside of 13.22%. Given DexCom’s stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Health Sciences Acquisitions Co. 2.

Volatility & Risk

DexCom has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Summary

DexCom beats Health Sciences Acquisitions Co. 2 on 11 of the 12 factors compared between the two stocks.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.